Skip navigation

News

Business Weeklywww.businessweekly.co.uk


ARECOR ANNOUNCES LAUNCH OF NEW WEBSITE

Cambridge, UK., 10 January 2018: Arecor Ltd (“the Company”), the leading formulation technology company, focused on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides to improve the treatment of diabetes and other conditions, is pleased to announce the launch of its new website at: www.arecor.com More »
11 January 2018

TTP Ventus micropump technology enables wearable treatment for sleep apnea

Cambridge, UK, 9th January 2018: TTP Ventus Ltd, a spin-out from TTP plc, created to bring disruptive new micropump technologies to market, has announced that Sommetrics Inc., is using its Disc Pump technology to enable aerSleep™, a novel negative-pressure system for the treatment of obstructive sleep apnea (OSA). Having recently received a Health Canada Medical Device License, aerSleep is now approved for marketing to patients in Canada. CE mark approval is expected Q4 2018. More »
10 January 2018

J A Kemp Opens Office in Paris

On 1 February 2018, J A Kemp, a leading firm of European and UK Patent and Trade Mark Attorneys, will open an office in Paris. This will be J A Kemp’s second office in continental Europe. The firm has had an office in Munich since the European Patent Office (EPO) was founded in the 1970s. The opening of the Paris office represents further expansion of the firm, which has grown 30% in headcount over the past five years and opened an additional UK office in Cambridge two years ago. More »
10 January 2018

Get on course to learn in 2018

Whatever your training needs, Cambridge Network's Learning Collaboration has a course to help you. Start the new year by focusing on enhancing your skills! Sign up now for one of its value-for-money-courses. More »
09 January 2018

"EUROPEAN PATENT FOR ARECOR'S PROPRIETARY TECHNOLOGY ENABLING HIGHLY CONCENTRATED BIOTHERAPEUTICS"

Cambridge, UK., 08 January 2018: Arecor Ltd (“the Company”), the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides, is pleased to announce the European Patent Office (“EPO”) has issued “Notice of Intention to Grant” for Arecor’s patent application protecting the Company’s proprietary technology used in the development of stable, low-viscosity formulations of highly concentrated protein therapeutics, including monoclonal antibodies such as trastuzumab or ustekinumab or fusion proteins such as abatacept. More »
08 January 2018

Cypralis and Gilead Sciences, Inc Agree Contract to Target Acute and Chronic Degenerative Diseases

This is a further step in the collaboration between the parties which follows a multi-year drug discovery collaboration between Selcia Ltd (Ongar, Essex) and Gilead (Foster City, California) under which Selcia’s chemists and biologists provided integrated drug discovery services to support Gilead’s liver disease research programmes. The research phase ended in 2013 and Selcia’s rights under the agreement have been subsequently transferred to Cypralis. More »
08 January 2018

New CRACK IT Solution: BrainBits®: Processing of Primary Rat and Mouse Tissues / Cells

BrainBits® is seeking collaborators that require a reliable source of primary rat and mouse tissues/cells for research and drug development More »
08 January 2018

Partnership opportunities - Applying QSAR models for improved toxicity testing of new chaemicals

KREATiS is seeking partners to develop the wider applicability of their iSafeRabbit High Accuracy QSAR (HA-QSAR) model to predict the skin and eye irritation potential of chemical substances and mixtures. More »
08 January 2018

Heptares scientists solve structure of complement C5a receptor, an important drug target for inflammatory and neurodegenerative

Publication in Nature highlights opportunities to target C5a receptor with selective small molecules via novel mechanism of action More »
04 January 2018

ARECOR AND JDRF ANNOUNCE SUCCESSFUL PRE-CLINICAL DEVELOPMENT

ARECOR AND JDRF ANNOUNCE SUCCESSFUL PRE-CLINICAL DEVELOPMENT OF STABLE RAPID-ACTING, ULTRA-CONCENTRATED INSULIN FOR THE SIGNIFICANTLY ENHANCED TREATMENT OF TYPE 1 DIABETES “Arecor’s proprietary insulin product to progress into human clinical trials in 2018” More »
04 January 2018

<< Previous   Page 2 of 35   Next >>